Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Somatostatin and primary hyperparathyroidism

M E Lucarotti1, J A Hamilton, J R Farndon

  • 1University Department of Surgery, Bristol Royal Infirmary, UK.

The British Journal of Surgery
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probable Encephaloid Disease of the Left Kidney.

Medical examiner (Chicago, Ill.)·2023
Same author

Suppression of Menses, with Good Health.

Medical examiner (Chicago, Ill.)·2023
Same author

Targeting GM-CSF for collagenase-induced osteoarthritis pain and disease in mice.

Osteoarthritis and cartilage·2020
Same author

Development of interest and enjoyment in adolescence. Part I. Attentional capacities.

Journal of youth and adolescence·2013
Same author

Development of interest and enjoyment in adolescence. Part II. Boredom and psychopathology.

Journal of youth and adolescence·2013
Same author

Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.

British journal of pharmacology·2013

Octreotide, a somatostatin analogue, showed potential in managing primary hyperparathyroidism by significantly reducing urinary calcium. While not significantly lowering serum calcium, it may help prevent stones and serve as a diagnostic tool.

Area of Science:

  • Endocrinology
  • Nephrology

Background:

  • Primary hyperparathyroidism lacks effective medical treatments.
  • Existing therapies like calcitonin and diphosphonates offer limited long-term control.

Purpose of the Study:

  • To evaluate the efficacy of octreotide, a somatostatin analogue, in managing primary hyperparathyroidism.
  • To assess octreotide's impact on serum calcium, parathyroid hormone, and urinary calcium levels.

Main Methods:

  • Twenty-one patients with primary hyperparathyroidism received subcutaneous octreotide (100 mcg twice daily) for six days before parathyroid surgery.
  • Fasting serum calcium and parathyroid hormone levels, along with 24-hour urinary calcium excretion, were measured pre- and post-treatment.

Main Results:

Related Experiment Videos

  • A statistically significant decrease in 24-hour urinary calcium excretion was observed.
  • No significant reduction in serum calcium levels was found.
  • Serum parathyroid hormone concentration remained unchanged post-treatment.

    • Conclusions:

    • Octreotide may offer a therapeutic option for primary hyperparathyroidism, particularly for patients unsuitable for surgery or with failed neck exploration.
    • It shows potential in ameliorating hypercalciuria, reducing kidney stone formation, and may serve as a diagnostic test for primary hyperparathyroidism.